New Australian melanoma management guidelines: the patient perspective

Button‐Sloan, Alison E; Thompson, John F

doi:10.5694/mja2.50813

Topics

Neoplasms

General medicine

The involvement of patient advocates should ensure that guidelines are rigorously patient‐focused

1 Melanoma Patients Australia, Brisbane, QLD
2 Melanoma Institute Australia, Sydney, NSW
3 University of Sydney, Sydney, NSW

Correspondence: john.thompson@melanoma.org.au

Acknowledgements:

The Australian Clinical practice guidelines for the diagnosis and management of melanoma were developed by Cancer Council Australia in partnership with Melanoma Institute of Australia and supported by the Skin Cancer College Australasia and the Australasian College of Dermatologists. John Thompson is the recipient of a National Health and Medical Research Council Program Grant (APP1093017). The grant had no direct role in this article.

Competing interests:

John Thompson has received honoraria for advisory board participation from BMS Australia and MSD Australia, and honoraria and travel support from GSK and Provectus.

1. Woolf SH, Grol R, Hutchinson A, et al. Potential benefits, limitations, and harms of clinical guidelines. BMJ 1999; 318: 527–530.
2. Addario BJ, Fadich A, Fox J, et al. Patient value: perspectives from the advocacy community. Health Expect 2018; 21: 57–63.
3. National Health and Medical Research Council. Clinical practice guidelines: the management of cutaneous melanoma. Sydney: Australian Cancer Network, endorsed 1999.
4. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, 2008. https://www.health.govt.nz/system/files/documents/publications/melanoma-guideline-nov08-v2.pdf (viewed Feb 2020).
5. Cancer Council Australia Melanoma Guidelines Working Party. Clinical practice guidelines for the diagnosis and management of melanoma. Sydney: Cancer Council, 2020. https://wiki.cancer.org.au/australia/Guidelines:Melanoma (viewed May 2020).
6. Eggermont AMM, Robert C, Ribas A. The new era of adjuvant therapies for melanoma. Nat Rev Clin Oncol 2018; 15: 535–536.
7. Testori AAE, Ribero S, Indini A, Mandalà M. Adjuvant treatment of melanoma: recent developments and future perspectives. Am J Clin Dermatol 2019; 20: 817–827.
8. Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG‐SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 2016; 17: 757–767.
9. Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel‐node metastasis in melanoma. N Engl J Med 2017; 376: 2211–2222.
10. Seth R, Messersmith H, Kaur V, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Oncol 2020;. https://doi.org/10.1200/JCO.20.00198. [Epub ahead of print].

Online responses are no longer available. Please refer to our instructions for authors page for more information.